November 14, 2019 11:27 AM ESTUpdated 11:42 AM

Sarepta picks up a slate of preclinical gene therapy programs, seeding new StrideBio deal with $48M upfront

Amber Tong

Having tasted early success in treating a number of muscular dystrophies with gene therapy, Sarepta is setting itself up to tackle more rare diseases. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sarepta picks up a slate of preclinical gene therapy programs, seeding new StrideBio deal with $48M upfront

Amber Tong

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

J&J reports durability data for bladder cancer 'pretzel' drug after FDA filing

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Sarep­ta picks up a slate of pre­clin­i­cal gene ther­a­py pro­grams, seed­ing new Stride­Bio deal with $48M up­front

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Sarepta picks up a slate of preclinical gene therapy programs, seeding new StrideBio deal with $48M upfront